GET DAILY SIGNALSSelectQuote (SLQT): Cash Flow Priorities Amid Medicare Headwinds
Key Takeaways
- SelectQuote operates a technology-enabled, direct-to-consumer platform that distributes senior (Medicare) insurance, life insurance, and healthcare services, including its SelectRx pharmacy.
- Over the trailing 30 days, SLQT shares have been roughly flat, trading near $0.41, after dipping into the low $0.30s in mid-October before recovering.
- Fiscal 2026 revenue rose 6% to $1.62 billion, while Healthcare Services became the company's largest revenue contributor at $845 million, up 14% year over year.
- Management is prioritizing cash generation and deleveraging, guiding to more than $60 million of operating cash flow for fiscal 2027.
- Medicare Advantage carrier discipline remains a key headwind, with approved policies expected to decline 10% to 15% in fiscal 2027.
- For deeper data, visit SelectQuote's Price Targets, Earnings, and Forecast pages to review analyst expectations and forward-looking metrics.
- Discover AI-driven trading strategies and automated market analysis by exploring Trending AI Robots.
Current Market Snapshot
SLQT has moved within a narrow, low-priced band in recent weeks, with shares changing hands near $0.40 to $0.41. That keeps the stock in sub-$1 territory, where even modest daily shifts can translate into noticeable percentage moves. Over the trailing 30 days, the shares have stayed essentially flat after a volatile period that took them toward $0.30 in mid-October before they stabilized.
The broader picture shows a company in transition. Investors are balancing a durable, cash-generating Medicare distribution business against ongoing Medicare Advantage pressures, a substantial debt and preferred-equity load, and pending legal matters. A price-to-sales multiple well below 1 reflects market skepticism, even as management maintains that the shares understate the platform's cash-flow potential. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business Overview and Competitive Position
Founded in 1985 and based in Overland Park, Kansas, SelectQuote runs a technology-enabled, direct-to-consumer distribution and engagement platform for insurance policies and healthcare services. It reports through three main segments: Senior, Healthcare Services, and Life, while scaling back its older Auto & Home operations.
The Senior segment handles Medicare Advantage, Medicare Supplement, Medicare Part D, and related senior health products, backed by a sizable licensed agent team and proprietary data-driven lead routing. Healthcare Services includes the SelectRx pharmacy, Healthcare Select risk-assessment services, and SelectPatient Management for chronic-condition support. The Life segment focuses on term life and final-expense products.
One thing that stands out is the company’s agent-led, technology-supported distribution model and strong carrier ties, which have delivered consistent mid-20% adjusted EBITDA margins in the Senior business. Healthcare Services has grown into the largest revenue contributor, positioning pharmacy and population-health offerings as a central growth area. From what I see, this shift supports longer-term stability.
Recent Developments Driving SLQT
SelectQuote released fourth-quarter and full-year fiscal 2026 results in late August 2026. Full-year revenue increased 6% to $1.62 billion, and adjusted EBITDA reached $109 million, exceeding the prior $90 million to $100 million outlook. Operating cash flow improved by $44 million year over year to roughly $32 million.
Healthcare Services, including SelectRx, produced $845 million in fiscal 2026 revenue, up 14%, even after the Inflation Reduction Act and an earlier pharmacy benefit manager reimbursement adjustment. The Senior segment generated $576 million in revenue, down 4%, while holding a 26% adjusted EBITDA margin despite continued Medicare Advantage carrier discipline.
Management views fiscal 2027 as a turning point, projecting $1.35 billion to $1.45 billion in revenue and $90 million to $115 million in adjusted EBITDA, with operating cash flow above $60 million and free cash flow near $50 million. The company also highlighted more than $30 million in annualized expense savings from AI-enabled tools, process improvements, and organizational efficiencies. I’m watching this closely as execution on these targets could influence sentiment.
At the same time, attention remains on the capital structure, including a $350 million non-convertible preferred issuance from 2025 carrying a 14.5% dividend rate, plus a U.S. Department of Justice qui tam action and a securities class action that the company is defending.
2026 Outlook and What Investors Should Watch
Looking ahead, the main variables for SLQT center on execution and cash generation rather than top-line expansion. Management’s fiscal 2027 guidance points to lower reported revenue, partly due to the Inflation Reduction Act’s impact on pharmacy revenue, yet materially higher operating cash flow. Investors will focus on whether SelectQuote meets its $60 million-plus operating cash flow target and sustains Healthcare Services margin expansion.
Medicare Advantage carrier behavior stays central to the Senior segment. With approved policies expected to decline 10% to 15% in fiscal 2027, the annual enrollment period and any shifts in carrier marketing budgets will shape near-term results. Deleveraging and potential refinancing also matter, given an approximate 12% blended cost of debt and preferred equity. Finally, outcomes of the pending DOJ action and securities litigation, along with any changes in analyst expectations, could affect sentiment. These factors are forward-looking and subject to change.
Exploring Tickeron’s AI Trading Bots for Market Insights
In my own research process, I have found value in reviewing Tickeron’s AI Trading Bots, which provide automated, data-driven perspectives on individual securities and broader market conditions. The platform offers hundreds of AI bots that trade thousands of tickers, and the curated Trending AI Robots section surfaces top-performing and relevant strategies to help filter out noise. Each bot differs in approach, holding period, and performance metrics, allowing investors to evaluate methodology and track record before incorporating quantitative signals into their analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SLQT's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for SLQT turned positive on September 29, 2026. Looking at past instances where SLQT's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SLQT's RSI Oscillator exited the oversold zone, 33 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on SLQT as a result. In 79 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
Following a +11.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLQT advanced for three days, in 204 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SLQT broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SLQT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.179) is normal, around the industry mean (2.657). P/E Ratio (-5.950) is within average values for comparable stocks, (18.633). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.322). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.058) is also within normal values, averaging (2.968).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. SLQT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a technology-enabled, direct-to-consumer distribution platform that provides consumers with a transparent and convenient venue to shop for complex senior health, life and auto & home insurance policies from a curated panel of insurance carriers
Industry InsuranceBrokersServices
Advertisement